CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world, with an estimated 63,030 new diagnosed cases and 13,360 deaths in 2017 [1]. Moreover, recurrent and metastatic cases increase annually and treatment is mostly limited to chemotherapy and radiation therapy. Targeted therapies using epidermal growth factor receptor (EGFR)-blocking monoclonal antibody, either alone or in combination with chemotherapy and/or radiotherapy, were recently introduced. However, treatments have been limited due to unfavorable toxicity and new treatment options are still urgently needed to improve patient outcomes [2].

Source: Oral Oncology - February 3, 2018 Category: Cancer & Oncology Authors: Yuk Pheel Park, Linchun Jin, Katie B. Bennett, Dunrui Wang, Kristianna M. Fredenburg, Jennifer E. Tseng, Lung ‐Ji Chang, Jianping Huang, Edward K.L. Chan Source Type: research